Induction of epithelial‐mesenchymal transition with O‐glycosylated oncofetal fibronectin | Zendy

Ding Yao | Zendy; Gelfenbeyn Kirill | Zendy; Freire-de-Lima Leonardo | Zendy; Handa Kazuko | Zendy; Hakomori Sen-itiroh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Induction of epithelial‐mesenchymal transition with O‐glycosylated oncofetal fibronectin

Author(s) -

Ding Yao,

Gelfenbeyn Kirill,

Freire-de-Lima Leonardo,

Handa Kazuko,

Hakomori Sen-itiroh

Publication year - 2012

Publication title -

febs letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.593

H-Index - 257

eISSN - 1873-3468

pISSN - 0014-5793

DOI - 10.1016/j.febslet.2012.05.020

Subject(s) - epithelial–mesenchymal transition , fibronectin , oncofetal antigen , transforming growth factor , mesenchymal stem cell , monoclonal antibody , biology , transition (genetics) , chemistry , microbiology and biotechnology , cancer research , antibody , immunology , extracellular matrix , biochemistry , gene , tumor associated antigen

Epithelial‐mesenchymal transition (EMT) has been shown to play a key role in embryogenesis and cancer progression. We previously found that fibronectin (FN) carrying O ‐GalNAc at a specific site is selectively expressed in cancer and fetal cells/tissues, and termed oncofetal FN (onfFN). Here, we show that (i) a newly‐established monoclonal antibody against FN lacking the O ‐GalNAc, termed normalFN (norFN), is useful for isolation of onfFN, (ii) onfFN, but not norFN, can induce EMT in human lung carcinoma cells, (iii) onfFN has a synergistic effect with transforming growth factor (TGF)β1 in EMT induction.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research